Aligos Therapeutics, Inc. (ALGS) Bundle
Understanding Aligos Therapeutics, Inc. (ALGS) Revenue Streams
Understanding Aligos Therapeutics’ Revenue Streams
As of September 30, 2024, Aligos Therapeutics reported a revenue from collaborations of $19,000 for the three months ended September 30, 2024, a significant decrease from $2.2 million for the same period in 2023. For the nine months ended September 30, 2024, revenue from collaborations was $311,000, down from $7.3 million in 2023.
Revenue from customers increased to $1.25 million in Q3 2024 from $1.085 million in Q3 2023. However, the nine-month period revealed a decline to $3.005 million in 2024 from $5.519 million in 2023, reflecting a decrease of 46%.
| Period | Revenue from Collaborations | Revenue from Customers |
|---|---|---|
| Q3 2024 | $19,000 | $1,250,000 |
| Q3 2023 | $2,154,000 | $1,085,000 |
| 9M 2024 | $311,000 | $3,005,000 |
| 9M 2023 | $7,329,000 | $5,519,000 |
The year-over-year revenue growth rate illustrates a dramatic decline in collaboration revenue by 99% for Q3 and 96% for the nine-month period. This decline is primarily attributed to the completion of the Amended Agreement with Merck in early 2024.
In contrast, revenue from customers showed a modest increase in Q3 but reflected a notable decrease over the nine-month comparison, indicating fluctuations in contract activity and project completion timelines. The revenue recognition methodology relies on the progress of projects and the corresponding costs incurred.
As of September 30, 2024, unrecognized revenue from collaborations stood at $0, down from $2.093 million in 2023. The changes in deferred revenue balances highlight the company's shifting revenue recognition landscape.
In addition to collaboration and customer revenue, government grants have been an essential part of the revenue structure. In 2024, Aligos received an additional $1.5 million from the NIH, bringing the total NIH grant funding to $1.5 million for that year. Furthermore, a contract with the NIAID was amended to a total of $9.8 million.
Overall, the revenue analysis indicates significant challenges and fluctuations for Aligos Therapeutics, with critical dependencies on collaboration agreements and government funding to sustain operations.
A Deep Dive into Aligos Therapeutics, Inc. (ALGS) Profitability
A Deep Dive into Aligos Therapeutics' Profitability
Gross Profit Margin: For the three months ended September 30, 2024, the company reported a revenue of $1.3 million, leading to a gross profit margin of approximately 0.04 (or 4%), compared to a revenue of $1.1 million in the same period of 2023, reflecting a slight increase.
Operating Profit Margin: The loss from operations for the three months ended September 30, 2024, was ($20.1 million), compared to a loss of ($19.1 million) for the same period in 2023. This results in an operating profit margin of -1540% for Q3 2024 and -1741% for Q3 2023.
Net Profit Margin: The net loss for the three months ended September 30, 2024, was ($19.3 million), resulting in a net profit margin of -1483%. For the same period in 2023, the net loss was ($18.0 million), yielding a net profit margin of -1650%.
| Period | Revenue ($ millions) | Gross Profit Margin (%) | Operating Profit Margin (%) | Net Profit Margin (%) |
|---|---|---|---|---|
| Q3 2024 | 1.3 | 4 | -1540 | -1483 |
| Q3 2023 | 1.1 | 3.5 | -1741 | -1650 |
Trends in Profitability Over Time: The company has consistently reported significant net losses over recent quarters. For the nine months ended September 30, 2024, the net loss was ($49.1 million), down from ($59.8 million) in the same period in 2023, indicating a trend towards reduced losses year-over-year.
Comparison of Profitability Ratios with Industry Averages: As of 2024, the biotechnology industry average net profit margin is approximately -30%. In comparison, the company's net profit margin of -1483% reflects a more substantial loss than the industry average.
Analysis of Operational Efficiency: Research and development expenses for the three months ended September 30, 2024, were $16.8 million, compared to $15.9 million in the same period of 2023. General and administrative expenses decreased to $4.6 million from $6.4 million, indicating improved cost management in administrative operations.
| Expense Type | Q3 2024 ($ millions) | Q3 2023 ($ millions) | Change ($ millions) |
|---|---|---|---|
| Research and Development | 16.8 | 15.9 | 0.9 |
| General and Administrative | 4.6 | 6.4 | -1.8 |
| Total Operating Expenses | 21.4 | 22.3 | -0.9 |
Debt vs. Equity: How Aligos Therapeutics, Inc. (ALGS) Finances Its Growth
Debt vs. Equity: How Aligos Therapeutics, Inc. Finances Its Growth
The financial health of Aligos Therapeutics, Inc. is a crucial aspect for investors to consider, especially when analyzing its debt versus equity structure. As of September 30, 2024, the company reported total liabilities of $38.3 million. This included current liabilities of $20.9 million and non-current liabilities of $17.4 million.
Overview of Debt Levels
Aligos Therapeutics carries both short-term and long-term debt. As of September 30, 2024, its total long-term debt was $188,000, while short-term obligations included operating lease liabilities of $3.4 million. The company's overall liabilities indicate a reliance on minimal debt financing to support its operations.
Debt-to-Equity Ratio
The debt-to-equity (D/E) ratio provides insight into the company's financial leverage. As of September 30, 2024, Aligos Therapeutics had total stockholders’ equity of $50.1 million. The D/E ratio can be calculated as follows:
D/E Ratio = Total Liabilities / Total Equity = $38.3 million / $50.1 million = 0.76.
This ratio is relatively low compared to the biotechnology industry average, which typically ranges from 0.8 to 1.5, indicating that the company maintains a conservative approach to leveraging debt for growth.
Recent Debt Issuances and Credit Ratings
Aligos Therapeutics primarily finances its operations through equity rather than debt. Despite its low debt levels, the company has engaged in various financing activities, such as a private placement in October 2023, which raised approximately $92.1 million. The company has not issued significant long-term debt instruments, and its credit rating has not been explicitly stated in recent reports.
Refinancing Activity
There has been no recent refinancing activity noted in the company's financial statements as of September 30, 2024. The absence of substantial long-term debt suggests that refinancing is not a current concern for Aligos Therapeutics.
Balancing Debt Financing and Equity Funding
Aligos Therapeutics has primarily relied on equity funding, which includes proceeds from the issuance of common stock, preferred stock, and warrants. The company has not generated revenue from product sales and has reported net losses of $49.1 million for the nine months ended September 30, 2024. This lack of revenue necessitates ongoing capital raising to finance research and development activities while minimizing debt accumulation.
| Financial Metric | Value (as of September 30, 2024) |
|---|---|
| Total Liabilities | $38.3 million |
| Total Stockholders' Equity | $50.1 million |
| Debt-to-Equity Ratio | 0.76 |
| Short-term Debt (Operating Lease Liabilities) | $3.4 million |
| Long-term Debt | $188,000 |
| Net Loss (9 months ended September 30, 2024) | $49.1 million |
| Private Placement Proceeds (October 2023) | $92.1 million |
Assessing Aligos Therapeutics, Inc. (ALGS) Liquidity
Assessing Aligos Therapeutics, Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current ratio is 4.05, calculated from current assets of approximately $80.0 million and current liabilities of $19.7 million.
Quick Ratio: The quick ratio stands at 3.75, with quick assets (current assets minus inventories) amounting to around $75.0 million and current liabilities remaining at $19.7 million.
Analysis of Working Capital Trends
Working capital has shown a positive trend, with total working capital as of September 30, 2024, reported at approximately $60.3 million, a notable increase from $45.5 million in the previous year, reflecting a stronger liquidity position.
Cash Flow Statements Overview
The cash flow statement for the nine months ended September 30, 2024, shows the following:
| Cash Flow Category | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net cash used in operating activities | $(62,340) | $(56,339) |
| Net cash provided by (used in) investing activities | $(38,251) | $44,988 |
| Net cash provided by financing activities | $258 | $392 |
| Net decrease in cash | $(100,333) | $(10,959) |
Potential Liquidity Concerns or Strengths
Despite the high current and quick ratios indicating a strong liquidity position, the company reported a significant net loss of $(49.1 million) for the nine months ended September 30, 2024, compared to $(59.8 million) for the same period in 2023. This continued trend of losses raises potential liquidity concerns for future operational sustainability.
The accumulated deficit as of September 30, 2024, stands at $(535.9 million), up from $(486.8 million) at the end of 2023, indicating ongoing challenges in achieving profitability.
Is Aligos Therapeutics, Inc. (ALGS) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the company has not generated any revenue from product sales and has significant net losses. The financial metrics relevant to the valuation analysis are as follows:
Price-to-Earnings (P/E) Ratio
Due to the absence of earnings, there is no P/E ratio available for the company.
Price-to-Book (P/B) Ratio
The company has a total stockholders’ equity of $50.1 million as of September 30, 2024. With a current market capitalization of approximately $100 million, the P/B ratio is calculated as follows:
P/B Ratio = Market Capitalization / Total Stockholders’ Equity = $100 million / $50.1 million = 1.99
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
As the company has not generated EBITDA, the EV/EBITDA ratio is also not applicable.
Stock Price Trends
Over the past 12 months, the stock price has fluctuated significantly:
- 12 months ago: $15.00
- Current price (as of September 30, 2024): $30.00
- Percentage increase: 100%
Dividend Yield and Payout Ratios
The company does not pay any dividends, thus the dividend yield and payout ratio are 0%.
Analyst Consensus on Stock Valuation
Analysts currently have the following ratings for the stock:
- Buy: 5
- Hold: 2
- Sell: 1
Financial Summary Table
| Metric | Value |
|---|---|
| Market Capitalization | $100 million |
| Total Stockholders' Equity | $50.1 million |
| P/B Ratio | 1.99 |
| Stock Price (Current) | $30.00 |
| Stock Price (1 Year Ago) | $15.00 |
| Percentage Increase in Stock Price | 100% |
| Dividend Yield | 0% |
| Analyst Buy Ratings | 5 |
| Analyst Hold Ratings | 2 |
| Analyst Sell Ratings | 1 |
The company continues to incur significant losses and has an accumulated deficit of $535.9 million as of September 30, 2024. The net loss for the nine months ended September 30, 2024, was $49.1 million. The company reported cash, cash equivalents, and investments amounting to $74.9 million.
Key Risks Facing Aligos Therapeutics, Inc. (ALGS)
Key Risks Facing Aligos Therapeutics, Inc.
The financial health of Aligos Therapeutics, Inc. is influenced by various internal and external risk factors. Understanding these risks is essential for investors considering an investment in the company.
Industry Competition
The biotechnology sector is highly competitive. Aligos Therapeutics faces competition from both established pharmaceutical companies and emerging biotech firms. The landscape includes numerous entities pursuing treatments for similar indications, particularly in chronic hepatitis B (CHB) and metabolic dysfunction associated with steatohepatitis (MASH). The need for continuous innovation and the ability to differentiate products significantly impacts market positioning.
Regulatory Changes
Regulatory scrutiny is a constant challenge in the biotech industry. The company has not yet commercialized any products and does not anticipate generating revenue from product sales for several years. The approval process for clinical trials and product commercialization is lengthy and can be unpredictable, influenced by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A failure to meet regulatory requirements could delay or prevent product approvals.
Market Conditions
Macroeconomic factors can also affect the company's financial health. Economic downturns can impact funding availability and investor sentiment, making it challenging to secure financing. The company has incurred significant losses, with an accumulated deficit of $535.9 million as of September 30, 2024. Such financial pressures can limit operational flexibility and strategic options.
Operational Risks
Aligos Therapeutics relies heavily on third-party vendors for clinical trials and manufacturing processes. Any disruption in these partnerships can lead to delays or increased costs. As of September 30, 2024, the company reported cash and cash equivalents of $35.3 million, which is critical for funding ongoing and future operations.
Financial Risks
The financial sustainability of Aligos Therapeutics is underpinned by its ability to raise additional capital. The company has not generated any revenue from product sales and has incurred losses in each fiscal year since inception. For the nine months ended September 30, 2024, the net loss was $49.1 million, compared to a loss of $59.8 million for the same period in 2023. This situation raises concerns about liquidity and the ability to fund future research and development activities.
Strategic Risks
The company's strategic decisions regarding drug development and partnerships are critical. The inability to establish successful collaborations or licensing agreements could hinder progress. The company expects to continue incurring substantial expenses related to its ongoing clinical development activities, which are projected to increase significantly.
Mitigation Strategies
To address these risks, Aligos Therapeutics has outlined several strategic initiatives:
- Engaging in partnerships with established pharmaceutical companies to leverage resources and expertise.
- Seeking government grants and funding to support research and development activities. For instance, the company was awarded a contract of $9.8 million from the National Institute of Allergies and Infectious Diseases (NIAID).
- Maintaining a robust cash position to navigate through potential financial challenges. As of September 30, 2024, the company had cash, cash equivalents, and investments totaling $74.9 million.
| Risk Category | Description | Current Impact |
|---|---|---|
| Industry Competition | High competition from established and emerging firms | Significant pressure on market share and innovation |
| Regulatory Changes | Unpredictable approval processes | Potential delays in product commercialization |
| Market Conditions | Economic downturns affecting funding | Increased difficulty in securing financing |
| Operational Risks | Reliance on third-party vendors | Possible delays or increased costs |
| Financial Risks | Need for additional capital | Liquidity concerns with an accumulated deficit of $535.9 million |
| Strategic Risks | Challenges in establishing successful collaborations | Hindered progress in drug development |
Future Growth Prospects for Aligos Therapeutics, Inc. (ALGS)
Future Growth Prospects for Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is positioned for potential growth driven by several key factors:
Analysis of Key Growth Drivers
- Product Innovations: The company is actively developing novel therapeutics targeting chronic hepatitis B (CHB), metabolic dysfunction associated steatohepatitis (MASH), and coronaviruses. Recent grants awarded include $1.5 million from the National Institutes of Health (NIH) in 2024, supporting ongoing research efforts.
- Market Expansions: Aligos has established collaborations and received funding contracts, such as an $8.5 million award from the National Institute of Allergies and Infectious Diseases (NIAID), which was increased to $9.8 million in March 2024.
- Acquisitions: The strategy includes potential in-licensing of new drug candidates to diversify its pipeline and enhance market presence.
Future Revenue Growth Projections and Earnings Estimates
The company has not generated revenue from product sales to date and projects continued losses. As of September 30, 2024, the accumulated deficit stood at $535.9 million. Revenue from collaborations for the nine months ended September 30, 2024, was $311,000, a significant decrease from $7.3 million in the same period of 2023.
Strategic Initiatives or Partnerships
Key strategic initiatives include:
- Collaborative agreements with major pharmaceutical companies, such as Merck, for joint development efforts.
- Government grants and contracts that provide essential funding for research and development projects.
Competitive Advantages That Position the Company for Growth
- Strong R&D Focus: Significant investment in research, with research and development expenses totaling $54.2 million for the nine months ended September 30, 2024.
- Collaborative Funding: The ability to secure substantial funding through collaborative arrangements, exemplified by the NIH and NIAID contracts.
| Growth Driver | Details |
|---|---|
| Product Innovations | Developing therapeutics for CHB and MASH; NIH grant of $1.5 million in 2024 |
| Market Expansion | $9.8 million contract with NIAID for coronavirus research |
| Revenue Projections | Accumulated deficit of $535.9 million; revenue from collaborations of $311,000 |
| R&D Expenses | $54.2 million for nine months ending September 30, 2024 |
Future growth opportunities are contingent upon the successful development and commercialization of drug candidates, alongside securing additional funding to support ongoing research and development efforts. The dynamic nature of the biotechnology industry presents both challenges and avenues for potential growth through innovation and strategic collaborations.
Aligos Therapeutics, Inc. (ALGS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Aligos Therapeutics, Inc. (ALGS) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Aligos Therapeutics, Inc. (ALGS)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Aligos Therapeutics, Inc. (ALGS)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.